Synopsis
MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.
Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.
Read the full story at MHRA (UK medicines regulator) ↗
